First Wave Biopharma shares are trading higher after the company achieved its enrollment target for its adrulipase Phase 2 SPAN trial for exocrine pancreatic insufficiency in cystic fibrosis patients.
Portfolio Pulse from Benzinga Newsdesk
First Wave Biopharma has achieved its enrollment target for the adrulipase Phase 2 SPAN trial, which focuses on exocrine pancreatic insufficiency in cystic fibrosis patients. This has led to an increase in the company's share price.
June 13, 2023 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
First Wave Biopharma's shares are trading higher after achieving the enrollment target for the adrulipase Phase 2 SPAN trial.
First Wave Biopharma's achievement of the enrollment target for the adrulipase Phase 2 SPAN trial is a positive milestone for the company. This accomplishment indicates progress in the development of their treatment for exocrine pancreatic insufficiency in cystic fibrosis patients, which could potentially lead to future revenue growth. As a result, investors are reacting positively, leading to an increase in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100